Varias empresas líderes en medicamentos innovadores superan significativamente las expectativas de rendimiento. El ETF de medicamentos innovadores en Hong Kong de mayor tamaño en la categoría, GF (513120), tiene una alta liquidez.

中证网讯 3月27日，港股窄幅震荡，石药集团、信达生物等创新药概念领涨。Wind数据显示，截至14:44 ，相关ETF产品中，港股创新药ETF广发（513120）盘中涨超5%，资金交投较为活跃，成交额持续位列全市场权益类ETF榜首。

As of March 26, the Hong Kong Innovative Drug ETF Guangfa (513120) has a latest scale of over 23.7 billion yuan, making it the largest Hong Kong innovative drug thematic index fund in the market, supporting T+0 trading. Moreover, funds have been continuously allocated recently, and since the beginning of this year, the Hong Kong Innovative Drug ETF Guangfa (513120) has seen a net inflow of over 1.3 billion yuan, exhibiting significant “capital-absorbing” characteristics.

消息面上，创新药龙头企业业绩超预期成为核心驱动因素。信达生物3月26日发布2025年业绩，实现总收入130.42亿元，同比增长38.4%，并首次实现全年盈利，其拥有18款上市产品，其中12款已纳入国家医保目录。3月25日，恒瑞医药发布2025年财报，报告期内营收和净利均再创新高，全年实现营业收入316.29亿元，同比增长13.02%；归母净利润77.11亿元，同比增长21.69%。此外，以诺诚健华、云顶新耀、中国生物医药为代表的多家创新药企扭亏为盈，行业进入盈利兑现期。

On the policy front, the 2026 government work report has for the first time listed biomedicine as an emerging pillar industry. Guosheng Securities believes that for the pharmaceutical sector, this means that the policy positioning of biomedicine is further upgraded from “nurturing emerging tracks” to “an important pillar direction for economic growth and industrial upgrading,” where innovative drugs, as the most core high-value-added links in the biomedicine industry, will benefit particularly clearly.

据悉，港股创新药ETF广发（513120；联接A/C类019670/019671）高度聚焦港股市场优质生物科技公司，覆盖创新药、基因治疗、前沿生物技术等细分领域龙头，生物制品、化学制药行业合计权重超85%，创新药“浓度”较高，成分股包含石药集团、康方生物、信达生物、三生制药等核心的港股18A生物科技公司。（王鹤静）

【来源：中国证券报·中证网】